Zynex(US:ZYXI) ZACKSยท2024-10-24 22:11Company Performance - Zynex Inc. reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.05 per share, but down from $0.10 per share a year ago, representing a 40% earnings surprise [1] - The company posted revenues of $49.97 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 0.86%, and showing a slight increase from $49.92 million year-over-year [1] - Over the last four quarters, Zynex has surpassed consensus EPS estimates only once and has not beaten consensus revenue estimates during the same period [1] Stock Outlook - Zynex shares have declined approximately 23.2% since the beginning of the year, contrasting with the S&P 500's gain of 21.5% [2] - The company's earnings outlook is uncertain, with unfavorable estimate revisions leading to a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [4] - Current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $53.85 million, and for the current fiscal year, it is $0.20 on revenues of $200.66 million [4] Industry Context - The Medical - Products industry, to which Zynex belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable industry outlook [5] - Another company in the same industry, Curaleaf Holdings, Inc., is expected to report a quarterly loss of $0.06 per share, reflecting a year-over-year change of +33.3%, with revenues projected at $348.52 million, up 4.6% from the previous year [5]